Landsberg Bennett & Dubbaneh’s Vertex Pharmaceuticals VRTX Stock Holding History

Landsberg Bennett & Dubbaneh’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$754K	Buy	4,180 +863	+26%	+$168K	0.1%	146
2021 Q2	$653K	Sell	3,317 -984	-23%	-$206K	0.08%	157
2021 Q1	$916K	Buy	4,301 +1,927	+81%	+$423K	0.13%	122
2020 Q4	$561K	Buy	+2,374	New	+$545K	0.09%	136

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Landsberg Bennett & Dubbaneh's VRTX Position: Q3 2021 in Review

Landsberg Bennett & Dubbaneh increased its Vertex Pharmaceuticals (VRTX) stake by 26% in Q3 2021, buying an estimated $168K and bringing the position to 4,180 shares worth $754K. The position accounts for 0.1% of the portfolio, ranked #146.

Landsberg Bennett & Dubbaneh first reported a position in VRTX in Q4 2020 and has held it in 4 quarters since. The position peaked at $916K in Q1 2021. 934 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

Landsberg Bennett & Dubbaneh held 4,180 shares of Vertex Pharmaceuticals worth $754K as of Q3 2021.
Landsberg Bennett & Dubbaneh bought 863 Vertex Pharmaceuticals shares in Q3 2021, an estimated $168K.
Vertex Pharmaceuticals made up 0.1% of Landsberg Bennett & Dubbaneh's portfolio in Q3 2021, its #146 holding.
Landsberg Bennett & Dubbaneh first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 4 quarters since.
Landsberg Bennett & Dubbaneh's Vertex Pharmaceuticals position peaked at $916K in Q1 2021.
934 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Landsberg Bennett & Dubbaneh's 13F filing for Q3 2021, filed 29 Oct 2021.